DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

Information source: Duke University
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetic Neuropathy

Intervention: Pregabalin (Drug); Placebo (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Duke University

Official(s) and/or principal investigator(s):
Wei Jiang, M.D., Principal Investigator, Affiliation: Duke University

Overall contact:
Tamara Foxworth, Phone: 919-668-3647, Email: tamara.foxworth@duke.edu

Summary

This study is designed to examine how pregabalin affects parameters of autonomic nerve regulation in correlation with change in pain, anxiety, and depressive symptoms in patients with diabetic neuropathy.

Clinical Details

Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment

Primary outcome: Assessing the change of parameters of autonomic nerve function such as Heart Rate Variability (HRV), Respiratory Sinus Arrhythmia (RSA), minute ventilation, and blood pressure by means of the LifeShirt

Secondary outcome: Assessing the change of pain symptoms upon treatment of pregabalin in comparison to placebo

Detailed description: This study is designed to primarily examine how pregabalin affects the autonomic nerve or sympathetic-parasympathetic regulation in patients with diabetic neuropathy and its relationship to neuropathic pain. The goals of this study include (1) assessing the change of parameters of autonomic nerve function such as HRV, RSA, minute ventilation, and changes in objective sleep parameters measured by means of the LifeShirt, upon treatment of pregabalin in comparison to placebo; (2) assessing the symptom change of neuropathic pain upon treatment of pregabalin in comparison to placebo; (3) assessing the change of anxiety symptoms upon treatment of pregabalin in comparison to placebo; (4) assessing the change of depressive symptoms upon treatment of pregabalin in comparison to placebo; (5) assessing the relationship of autonomic nerve function with neuropathic pain at baseline prior to treatment and the correspondences to the study drug; (6) assessing the relationship of autonomic nerve function with anxiety and depressive symptoms at baseline prior to treatment and their correspondences to the study drug; (7) identifying sensitive and reliable parameters of autonomic nerve regulation as predictor(s) of the severity and improvement of neuropathic pain and/or anxiety; and (8) to assess the change in objective sleep parameters (EEG/EOG) by means of the LifeShirt, upon treatment of pregabalin in comparison to placebo

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Outpatients aged 18 years or older

- Meet criteria for diagnosis of diabetic neuropathy

- Average daily pain scores greater than or equal to 4 by Visual Analog Scale

- Ability to give informed consent

- No pregnancy

Exclusion Criteria:

- Patients with clinically significant psychiatric disorders requiring vigorous

interventions, i. e., moderate to severe depressive disorder, psychotic disorders, PTSD, OCD, panic disorder, substance abuse, or personality disorders, or active suicidal/homicidal ideations, or past history of active suicidal ideation and/or attempts

- Patients on gabapentin which cannot be discontinued, meaning a dose greater than

1200mg. If a patient is on a dose of gabapentin that is less than 1200mg and he or she is willing to stop taking the medication, he or she can participate in the study. These patients must take the last dose of gabapentin the night before starting the study.

- Patients being non-compliant with diabetic control

- Inability to wear the LifeShirt

- Unable to participate or answer questions using a PDA input device

Locations and Contacts

Tamara Foxworth, Phone: 919-668-3647, Email: tamara.foxworth@duke.edu

Duke University Medical Center, Durham, North Carolina 27710, United States; Recruiting
Tamara Foxworth, Phone: 919-668-3647, Email: tamara.foxworth@duke.edu
Wei Jiang, M.D., Principal Investigator
Additional Information

Starting date: March 2006
Ending date: May 2008
Last updated: December 14, 2007

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012